From June 2007 to September 2008, aortic valvular prostheses were successfully implanted with the transcatheter technique in 150 patients with high-grade aortic stenosis. The 30-day mortality was 11.8%, which can be compared to a figure of 24% for conventional aortic valve replacement surgery. The most common post-procedural complications were cardiac arrhythmia, vascular problems, and cerebrovascular events. Six months after the procedure, the patients' clinical condition had markedly improved, and the authors were able to demonstrate good hemodynamic functioning of the new prostheses.
Calcific aortic stenosis is the most common acquired heart valve defect in Western countries, with a prevalence of more than 3% in persons over age 75. Up to the present time, the treatment of choice for high-grade aortic stenosis has been surgical aortic valve replacement. As many as 60% of patients, however, cannot be operated on because of advanced age and major comorbidities, even though they suffer from severe symptoms and have a poor prognosis under conservative treatment.
The advantage of transcatheter valve implantation is that it can be performed on the beating heart without the need for a heart-lung machine. In the procedure, an aortic valve prosthesis crimped to fit inside the catheter is brought into aortic position and then unfolded. The catheter can be inserted transarterially, usually by way of a femoral artery puncture, or transapically, i.e., through the left ventricular apex. The technical feasibility of the procedure has already been demonstrated at multiple centers around the world.
Article: Sabine Bleiziffer, Hendrik Ruge, Domenico Mazzitelli, Christian Schreiber, Andrea Hutter, Markus Krane, Robert Bauernschmitt, Rüdiger Lange, 'Valve Implantation on the Beating Heart', Dtsch Arztebl Int 2009; 106(14): 235-41
- Blood Clots May Complicate Aortic Valve Replacements
- Transcatheter Technologies Successfully Performs In Vivo Implantation Of The Trinity Transapical Aortic Valve System
- The Downside To Plant Sterols
- Leading Medical Device Manufacturers Of CE-Marked THV Devices Sign Contracts With ClinFlows
- Two-Year Follow-Up Data Demonstrates Preservation Of Adequate Mitral Valve Area In Patients Treated With The MitraClip(R) System